News

Rolling Out1d
The fall of 23andMe and what it means for your DNA
The fall of 23andMe raises privacy concerns as Regeneron buys its genetic database for $256M after bankruptcy.
Regeneron Pharmaceuticals to buy 23andMe for $256M — taking control of genetic data of millions
It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly ...
Regeneron Continues To Regenerate Its Drug Pipeline, While Keeping Leverage Down
Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...
Yahoo Finance21d
Q1 2025 Regeneron Pharmaceuticals Inc Earnings Call
Thank you for your interest in Regeneron and welcome to our first quarter 2025 earnings conference call. An archive and transcript of this call will be available on Regeneron's Investor ...
Morningstar29d
Regeneron Announces Investor Conference Presentations
The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and ...
STAT4d
Amgen loses $400 million antitrust battle to Regeneron
Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron ...
Fintel on MSN6d
Citigroup Upgrades Regeneron Pharmaceuticals (REGN)
Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from ...
Regeneron wins over $400M jury award as Amgen found liable in antitrust case
Regeneron (REGN) wins $400M in damages as jury finds Amgen (AMGN) violated antitrust laws by promoting its heart drug Repatha ...